Dihexa vs Selank
Both Dihexa and Selank are used for cognitive. Here's how their evidence, dosing, and regulatory status actually compare.
Dihexa
Evidence CDihexa (PNB-0408)
An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.
View full Dihexa profile →Selank
Evidence BSelank (TP-7)
A synthetic analog of tuftsin with anxiolytic and nootropic properties. Modulates GABA and serotonin systems to reduce anxiety without sedation.
View full Selank profile →Side-by-Side
| Attribute | Dihexa | Selank |
|---|---|---|
| Evidence Grade | C | B |
| FDA Status | Not FDA-approved — research compound (HGF/c-Met-mimetic) | Not FDA-approved in US — approved in Russia as anxiolytic |
| Typical Dose | 8–45 mg orally daily (research-only) | 200–400 mcg intranasal, evening |
| Clinics Indexed | 10 | 72 |
| Categories | cognitive, neuroprotection | cognitive, anxiety |
Key reported benefits — Dihexa
- ✓Synaptogenesis (preclinical)
- ✓Memory improvement (animal)
- ✓Possible Alzheimer's relevance
Key reported benefits — Selank
- ✓Anxiety reduction
- ✓Stress resilience
- ✓Cognitive clarity
- ✓Immune modulation
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.